{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T12:13:17Z","timestamp":1789819997857,"version":"4.0.1"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"an NIHR Academic Clinical Lectureship"},{"DOI":"10.13039\/501100007155","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/Z504026\/1"],"award-info":[{"award-number":["MR\/Z504026\/1"]}],"id":[{"id":"10.13039\/501100007155","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,6]]},"DOI":"10.1093\/bjd\/ljaf404","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T12:43:16Z","timestamp":1762173796000},"page":"3-4","source":"Crossref","is-referenced-by-count":1,"title":["Psoriasis at high-impact sites: shifting the paradigm"],"prefix":"10.1093","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1895-6070","authenticated-orcid":false,"given":"Teresa","family":"Tsakok","sequence":"first","affiliation":[{"name":"St John\u2019s Institute of Dermatology, King\u2019s College London and Guy\u2019s and St Thomas\u2019 NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1831-074X","authenticated-orcid":false,"given":"Zenas Z N","family":"Yiu","sequence":"additional","affiliation":[{"name":"Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester , Manchester ,","place":["UK"]},{"name":"Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre , Manchester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9918-1144","authenticated-orcid":false,"given":"Catherine\u00a0H","family":"Smith","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, King\u2019s College London and Guy\u2019s and St Thomas\u2019 NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"2026010607272266400_ljaf404-B1","author":"National Institute for Health and Care Excellence"},{"key":"2026010607272266400_ljaf404-B2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jaad.2019.08.026","article-title":"International Psoriasis Council Board Members and Councilors. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council","volume":"82","author":"Strober","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2026010607272266400_ljaf404-B3","article-title":"SPECTREM phase IIIb clinical trial results through week 16: guselkumab efficacy and safety in the treatment of low body surface area moderate psoriasis with high-impact site involvement","volume":"194","author":"Gold","year":"2026","journal-title":"Br J Dermatol"},{"key":"2026010607272266400_ljaf404-B4","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2026010607272266400_ljaf404-B5","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"2026010607272266400_ljaf404-B6","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N Engl J Med"},{"key":"2026010607272266400_ljaf404-B7","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"UNCOVER-1 Study Group; UNCOVER-2 Study Group; UNCOVER-3 Study Group. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N Engl J Med"},{"key":"2026010607272266400_ljaf404-B8","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"ERASURE Study Group; FIXTURE Study Group. Secukinumab in plaque psoriasis \u2013 results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"key":"2026010607272266400_ljaf404-B9","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"2026010607272266400_ljaf404-B10","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1001\/jamadermatol.2025.1849","article-title":"VISIBLE Trial Investigators. Guselkumab for moderate to severe scalp psoriasis across all skin tones: Cohort B of the VISIBLE Randomized Clinical Trial","volume":"161","author":"McMichael","year":"2025","journal-title":"JAMA Dermatol"},{"key":"2026010607272266400_ljaf404-B11","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaad.2024.03.025","article-title":"Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b study","volume":"93","author":"Gebauer","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"2026010607272266400_ljaf404-B12","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.jaad.2025.05.1445","article-title":"International Psoriasis Council psoriasis disease severity reclassification: update on validity, acceptance, and implementation","volume":"93","author":"Strober","year":"2025","journal-title":"J Am Acad Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljaf404\/65137270\/ljaf404.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/194\/1\/3\/65137270\/ljaf404.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/194\/1\/3\/65137270\/ljaf404.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T12:27:31Z","timestamp":1767702451000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/194\/1\/3\/8313675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,11,4]]},"published-print":{"date-parts":[[2026,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljaf404","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,11,4]]}}}